Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
12 September 2024
| Name: | ALCHEMIA LIMITED (ACL) (This company subsequently changed its name and is now THE SUSTAINABLE NUTRITION GROUP LTD. You should refer to that name for Status.) | |||||||||
| Date of Listing: | 23 December 2003 | |||||||||
| Subsequent Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now THE SUSTAINABLE NUTRITION GROUP LTD. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now THE SUSTAINABLE NUTRITION GROUP LTD. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now THE SUSTAINABLE NUTRITION GROUP LTD. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | 25/10/2021 | |
| AUSTRALIAN PRIMARY HEMP LIMITED | 15/10/2019 | 25/10/2021 |
| ALCHEMIA LIMITED | 15/10/2019 |
REGISTRY:
Link Market Services Brisbane
Level 21, 10 Eagle Street
Brisbane QLD 4000
Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
The suspension of trading in the securities of Australian Primary Hemp Limited will lift and the company reinstated to official quotation at the commencement of trading on Friday, 18 October 2019 at 10:00am AEDT, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The company raised $5,700,000 pursuant to the offer under its replacement prospectus dated 16 September 2019 by the issue of 28,500,000 at an issue price of $0.20 per share. | 17/10/2019 |
name changed to Australian Primary Hemp Limited | 15/10/2019 |
The offers in the replacement prospectus have now closed. The company has successfully raised $5,700,000 through the issue of 28,500,000 fully paid ordinary shares at $0.20 per share. Completion of the share sale agreement between the company, ACN 614 061 951 Pty Ltd and hte shareholders of APH with respect to the acquisition of 100% of the issued capital in APH by the company has now occurred. The company has issued 15,225,000 fully paid ordinary shares to the shareholders of APH as consideration in accordance with the share sale agreement. | 03/10/2019 |
The company has completed the consolidation of its share capital on a one (1) for twenty (20) basis. The consolidation was approved by shareholders at the AGM held on 16 September 2019. The post-consolidation shares of the company are as follows: fully paid ordinary shares - 324,723,621 (pre) - 16,234,845 (post). The consolidation will take effect from 27 September 2019. | 27/09/2019 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 26/09/2019 |
The company releases a replacement prospectus to acquire fully paid ordinary shares in Alchemia Limited. | 16/09/2019 |
The company releases the results of its annual general meeting. | 16/09/2019 |
The company releases a notification of consolidation of its securities. Shareholders will get 1 share for every 20 presently owned. | 13/09/2019 |
The company's AGM will be held at Holding Redlich Lawyers, Level 8, 555 Bourke Street, Melbourne VIC 3000 on Monday, 16 September 2019 commencing at 10:00am (Melbourne time). | 12/08/2019 |
The company releases its Appendix 4G and Corporate Governance Statement. | 01/08/2019 |
The company lodges its Appendix 4E and 2019 Annual Report. | 01/08/2019 |
The company lodges an Appendix 4C - Quarterly. | 19/07/2019 |
The company has entered into a share sale agreement pursuant to which it has conditionally agreed to acquire 100% of the issued capital of Australian Primary Hemp. APH is one of Australia's leading hemp producers with a demonstrated execution capability and diversified business operations across the value chain, owning quality production assets in Victoria. APH has a vast network of growers across the east coast of Australia with large scale hemp production capability. Since inception APH's network of growers have procured over 500T of hemp grain. Since the legalisation of hemp in Australia, the industry has experienced rapid growth and APH is strongly positioned to benefit from the growth in hemp demand in Australia and internationally. "¢ Incoming APH executive team and Board of Directors have significant agricultural and hemp industry experience. Alchemia will change its name to "Australian Primary Hemp Limited" on settlement of the acquisition. | 21/06/2019 |
The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 1 July 2019, or when an announcement with regard to ASX's determination is released to the market. | 03/06/2019 |
The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the Company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The Company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 3 June 2019, or when an announcement with regard to ASX's determination is released to the market. | 30/04/2019 |
The company lodges its Appendix 4C - Quarterly. | 18/04/2019 |
The securities of Alchemia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ACL, pending the release of an announcement regarding a proposed change to the nature and scale of the Company's activities. | 29/03/2019 |
The suspension of trading in the securities of Alchemia Limited will be lifted immediately, following the receipt of additional information about the ongoing activities of the Company. | 16/06/2016 |
The company provides an update on company activities. | 16/06/2016 |
The company advises that the ASX has suspended trading of the Company's securities effective close of trading on Tuesday 14 June 2016 due to ASX's opinion that the Company is not in compliance with ASX Listing Rule 12.1. The Company has this morning provided a submission to the ASX to demonstrate its ongoing compliance with Chapter 12 and specifically 12.1 of the Listing Rules. The ASX is currently in the process of reviewing this submission. | 15/06/2016 |
The securities ofAlchemia Limited (the "Company")will be suspended from quotation at the close oftrading today, Tuesday, 14 June 2016 in accordance with listing rule 17.3, as ASX has determined that the Company does not have sufficient operations to warrant the continued quotation of its securities in accordance with listing rule 12.1. The suspension will continue until either the Company is able to demonstrate compliance with Chapter 12 of the Listing Rules, or it complies with Chapters 1 and 2 of the Listing Rules. | 14/06/2016 |
we understand that on or about this date the company made a capital return of 9.3 cents per share | 01/02/2016 |
we understand that on or about this date the company made a capital return of 9.3 cents per share | 01/02/2016 |
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding the Company's profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL | 29/05/2015 |
The company releases its Fondaparinux Result for Quarter Ended 31 March 2015. | 29/05/2015 |
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL | 26/05/2015 |
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following the Company" update in relation to the proposed demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL | 21/12/2012 |
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, whilst it continues negotiations relating to the demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL Adrian Smythe | 17/12/2012 |
we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - demerge its wholly owned subsidiary Alchemia Oncology Pty Ltd - this corporate event may appear elsewhere in this company record | 18/10/2012 |
The suspension of trading in the securities of Australian Primary Hemp Limited will lift and the company reinstated to official quotation at the commencement of trading on Friday, 18 October 2019 at 10:00am AEDT, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The company raised $5,700,000 pursuant to the offer under its replacement prospectus dated 16 September 2019 by the issue of 28,500,000 at an issue price of $0.20 per share. | 17/10/2019 |
name changed to Australian Primary Hemp Limited | 15/10/2019 |
The offers in the replacement prospectus have now closed. The company has successfully raised $5,700,000 through the issue of 28,500,000 fully paid ordinary shares at $0.20 per share. Completion of the share sale agreement between the company, ACN 614 061 951 Pty Ltd and hte shareholders of APH with respect to the acquisition of 100% of the issued capital in APH by the company has now occurred. The company has issued 15,225,000 fully paid ordinary shares to the shareholders of APH as consideration in accordance with the share sale agreement. | 03/10/2019 |
The company has completed the consolidation of its share capital on a one (1) for twenty (20) basis. The consolidation was approved by shareholders at the AGM held on 16 September 2019. The post-consolidation shares of the company are as follows: fully paid ordinary shares - 324,723,621 (pre) - 16,234,845 (post). The consolidation will take effect from 27 September 2019. | 27/09/2019 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 26/09/2019 |
The company releases a replacement prospectus to acquire fully paid ordinary shares in Alchemia Limited. | 16/09/2019 |
The company releases the results of its annual general meeting. | 16/09/2019 |
The company releases a notification of consolidation of its securities. Shareholders will get 1 share for every 20 presently owned. | 13/09/2019 |
The company's AGM will be held at Holding Redlich Lawyers, Level 8, 555 Bourke Street, Melbourne VIC 3000 on Monday, 16 September 2019 commencing at 10:00am (Melbourne time). | 12/08/2019 |
The company releases its Appendix 4G and Corporate Governance Statement. | 01/08/2019 |
The company lodges its Appendix 4E and 2019 Annual Report. | 01/08/2019 |
The company lodges an Appendix 4C - Quarterly. | 19/07/2019 |
The company has entered into a share sale agreement pursuant to which it has conditionally agreed to acquire 100% of the issued capital of Australian Primary Hemp. APH is one of Australia's leading hemp producers with a demonstrated execution capability and diversified business operations across the value chain, owning quality production assets in Victoria. APH has a vast network of growers across the east coast of Australia with large scale hemp production capability. Since inception APH's network of growers have procured over 500T of hemp grain. Since the legalisation of hemp in Australia, the industry has experienced rapid growth and APH is strongly positioned to benefit from the growth in hemp demand in Australia and internationally. "¢ Incoming APH executive team and Board of Directors have significant agricultural and hemp industry experience. Alchemia will change its name to "Australian Primary Hemp Limited" on settlement of the acquisition. | 21/06/2019 |
The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 1 July 2019, or when an announcement with regard to ASX's determination is released to the market. | 03/06/2019 |
The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the Company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The Company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 3 June 2019, or when an announcement with regard to ASX's determination is released to the market. | 30/04/2019 |
The company lodges its Appendix 4C - Quarterly. | 18/04/2019 |
The securities of Alchemia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ACL, pending the release of an announcement regarding a proposed change to the nature and scale of the Company's activities. | 29/03/2019 |
The suspension of trading in the securities of Alchemia Limited will be lifted immediately, following the receipt of additional information about the ongoing activities of the Company. | 16/06/2016 |
The company provides an update on company activities. | 16/06/2016 |
The company advises that the ASX has suspended trading of the Company's securities effective close of trading on Tuesday 14 June 2016 due to ASX's opinion that the Company is not in compliance with ASX Listing Rule 12.1. The Company has this morning provided a submission to the ASX to demonstrate its ongoing compliance with Chapter 12 and specifically 12.1 of the Listing Rules. The ASX is currently in the process of reviewing this submission. | 15/06/2016 |
The securities ofAlchemia Limited (the "Company")will be suspended from quotation at the close oftrading today, Tuesday, 14 June 2016 in accordance with listing rule 17.3, as ASX has determined that the Company does not have sufficient operations to warrant the continued quotation of its securities in accordance with listing rule 12.1. The suspension will continue until either the Company is able to demonstrate compliance with Chapter 12 of the Listing Rules, or it complies with Chapters 1 and 2 of the Listing Rules. | 14/06/2016 |
we understand that on or about this date the company made a capital return of 9.3 cents per share | 01/02/2016 |
we understand that on or about this date the company made a capital return of 9.3 cents per share | 01/02/2016 |
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding the Company's profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL | 29/05/2015 |
The company releases its Fondaparinux Result for Quarter Ended 31 March 2015. | 29/05/2015 |
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL | 26/05/2015 |
The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following the Company" update in relation to the proposed demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL | 21/12/2012 |
The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, whilst it continues negotiations relating to the demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL Adrian Smythe | 17/12/2012 |
we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - demerge its wholly owned subsidiary Alchemia Oncology Pty Ltd - this corporate event may appear elsewhere in this company record | 18/10/2012 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 08/01/2018 | David Lamm | 48,550,000 | $0.016 | $798,309 | |
| 04/01/2018 | Darren Book | 256,659 | $0.021 | $5,447 | |
| 30/06/2017 | Darren Book | 1,000,000 | $0.008 | $8,000 | |
| 12/03/2013 | Melvyn Bridges | On market | 53,750 | $0.370 | $19,888 |
| 25/11/2011 | Melvyn Bridges | On market | 94,000 | $0.320 | $30,042 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Cameron Petricevic | Chairman | 06/06/2018 |
| Pauline Gately | Director | 02/10/2019 |
| Charles Mann | Director | 02/10/2019 |
| James Hood | Director | 02/10/2019 |
| Michael Sapountzis | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Lynden Polonsky | Director | 04/03/2019 | 02/10/2019 |
| Melanie Leydin | Director, CFO | 11/04/2016 | 02/10/2019 |
| Simon Gennari | Non Exec Chairman | 29/02/2016 | 04/03/2019 |
| Darren Book | Non Exec Director | 12/12/2016 | 04/03/2019 |
| David Lamm | Non Exec Director | 07/03/2016 | 06/06/2018 |
| Nathan Drona | Non Exec Director | 22/03/2013 | 25/11/2016 |
| Tracie Ramsdale | Non Exec Director | 26/04/2007 | 29/06/2016 |
| Jenni Pilcher | CFO | 01/09/2014 | 11/04/2016 |
| Ken Poutakidis | Non Exec Chairman | 26/06/2015 | 29/02/2016 |
| Timothy Hughes | Chairman | 15/07/2013 | 09/07/2015 |
| Santo Costa | Non Exec Chairman | 01/03/2014 | 10/06/2015 |
| Susan Kelley | Non Exec Director | 22/03/2013 | 10/06/2015 |
| Thomas Liquard | CEO | 16/12/2013 | 11/11/2014 |
| Charles Walker | CEO | 24/02/2014 | |
| Melvyn Bridges | Non Exec Chairman | 02/10/2003 | 13/07/2013 |
| Nerolie Withnall | Director | 27/10/2003 | 04/07/2013 |
| Peter Smith | CEO | 26/04/2007 | 25/01/2013 |
| Carlo Montagner | Non Exec Director | 07/03/2008 | 22/11/2011 |
| Peter Andrews | Non Exec Director | 02/11/1995 | 21/11/2008 |
| Julian Clark | Non Exec Director | 21/11/2008 | |
| Errol Malta | Non Exec Director | 27/10/2003 | 30/09/2007 |
| Kevin Healey | Non Exec Director | 12/03/1998 | 18/09/2006 |
| Nicholas Mathiou | Alternate Director | 01/08/2005 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
